NASDAQ: DNLI

Company Drug

Denali Therapeutics Faces Setback as ALS Trial Fails to Meet Primary Endpoint

Fineline Cube Feb 19, 2024

Denali Therapeutics (NASDAQ: DNLI) has announced disappointing results from a Phase II trial of its...

Company

Denali Therapeutics and Takeda Halt Development of Alzheimer’s Drug Candidate TAK-920/DNL919

Fineline Cube Aug 10, 2023

US-based biopharmaceutical company Denali Therapeutics Inc., (NASDAQ: DNLI) has announced in its Q2 2023 financial...

Policy / Regulatory

U.S. Tariffs on Pharmaceuticals and Their Impact on China’s Medical Industry

Company Drug

Sichuan Biokin Launches Phase III Trial for BL-B01D1 in Urothelial Carcinoma

Company Drug

AbbVie’s Rinvoq Approved in EU for Giant Cell Arteritis

Company Drug

Bristol-Myers Squibb’s Opdivo/Yervoy Combo Approved for MSI-H Colorectal Cancer